Attention!

What is the drug DEFERASIROX-CHEMRAR

The active substance of the drug DEFERASIROX-CHEMRAR is deferasirox, which belongs to the pharmacotherapeutic group called: "other medicinal products; iron-binding agents".

Patients with various forms of anemia (for example, thalassemia, sickle cell anemia, or myelodysplastic syndrome (MDS)) they may need multiple blood transfusions. However, repeated blood transfusions can cause excessive iron content in the body. This is because the blood contains iron, and the body does not have a natural mechanism for removing excess iron, which you get with blood transfusions. Patients with thalassemia syndromes that do not depend on blood transfusions may also develop iron overload over time, mainly due to increased absorption of iron from food in response to low blood cell counts. Over time, excessive iron content can cause damage to important organs, such as the liver and heart. Medications called iron chelators are used to remove excess iron from the body and reduce the associated risk of organ damage.

The drug DEFERASIROX-CHEMRAR is able to chelate (bind) iron ions and thereby remove excess iron from the body (this condition is called iron overload). 

Packaging

7 tablets each in a contoured cell package (blister) made of PVC/PE/PVDH film and aluminum foil printed varnished.

4 or 12 contour cell packages (blisters) together with a leaflet are placed in a pack of cardboard.

Indications for use

- DEFERASIROX-CHEMRAR is indicated for adults and children aged 2 years and older for the treatment of chronic post-transfusion iron overload.

- DEFERASIROX-CHEMRAR is indicated for adults and children aged 10 years and older for the treatment of chronic non-transfusion iron overload in patients with thalassemia.

Efficacy and safety studies

In accordance with current legislation, the drug has proven its effectiveness, safety and quality during state registration. For registration purposes, a bioequivalence study was conducted with the original (reference) medicinal product.